Compare GSK plc (GSK) vs Main Street Capital Corporation (MAIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Main Street Capital Corporation — how do they compare? GSK plc trades at $46.4 (market cap $91.88B), while Main Street Capital Corporation trades at $54.06 (market cap $5.09B). The key difference: GSK plc is far larger — about 18.1× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays the higher dividend (5.84%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Main Street Capital Corporation for 88 Days on average.
| GSK | MAIN | |
|---|---|---|
Market Cap | $91.88B | $5.09B |
Volume | 7,730,529 | 524,060 |
Sector | Health | Financials |
52-Week High | $61.18 | $64.60 |
52-Week Low | $43.24 | $49.63 |
Typical Hold Time | 93 Days | 88 Days |
Enterprise Value | $111.88B | $7.54B |
Dividend Yield | 3.9% | 5.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
Main Street Capital (MAIN) trades at $54.305, up 0.23% on the day, with a bearish technical outlook as moving averages and oscillators signal selling pressure. Fundamentally, the company maintains strong profitability with an 80.77% net income margin and a P/E of 10.94, though revenue declined to $592 million in 2025 from $601 million in 2024. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026. The stock pays consistent monthly dividends, with the latest being $0.27 per share.
The investment outlook is cautious; analyst consensus is a 'Hold' with a $58.33 price target, indicating modest upside. Risks include softening earnings, a premium valuation at 1.62x NAV, and sensitivity to interest rates. The bearish technicals and high hold ratings suggest limited near-term catalysts, but the dividend yield near 8% and robust ROE of 14.92% provide income support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →
